Sixiang Shi1, #, Feng Chen2, #, Shreya Goel1, Stephen A. Graves3, Haiming Luo2, Charles P. Theuer4, Jonathan W. Engle3, Weibo Cai1, 2, 3, 5, *
|
Abstract
Full Text Html
PDF w/ Links Export Citation Figures
|
1Department of Materials Science and Engineering, University of Wisconsin-Madison, WI, USA 2Department of Radiology, University of Wisconsin-Madison, Madison, WI, 53705-2275 USA 3Department of Medical Physics, University of Wisconsin-Madison, WI, USA 4TRACON Pharmaceuticals, Inc., San Diego, CA, USA 5University of Wisconsin Carbone Cancer Center, Madison, WI, USA
+Show more |
Nano-Micro Lett. (2018) 10: 65
|
First Online: 14 June 2018 (Article)
|
DOI:10.1007/s40820-018-0216-2
|
*Corresponding author. E-mail: wcai@uwhealth.org |
Abstract
|
Silica nanoparticles have been one of the most promising nanosystems for biomedical applications due to their facile surface chemistry and non-toxic nature. However, it is still challenging to effectively deliver them into tumor sites and non-invasively visualize their in vivo biodistribution with excellent sensitivity and accuracy for effective cancer diagnosis. In this study, we design a yolk/shell structured silica nanosystem 64Cu-NOTA-QD@HMSN-PEG-TRC105, which can be employed for tumor vasculature targeting and dual-modality PET/optical imaging, leading to superior targeting specificity, excellent imaging capability and more reliable diagnostic outcomes. By combining vasculature targeting, pH-sensitive drug delivery and dual-modality imaging into a single platform, as-designed yolk/shell structured silica nanosystems may be employed for the future image-guided tumor-targeted drug delivery, to further enable cancer theranostics.
Keywords
Hollow mesoporous silica nanoparticle (HMSN); Quantum dot (QD); Molecular imaging; Positron emission tomography (PET); Optical imaging; CD105/endoglin
|
View: Full Text HTML | PDF w/ Links